Literature DB >> 3890202

Isoniazid interactions.

A M Baciewicz, T H Self.   

Abstract

Isoniazid is an antituberculous drug that is usually administered for nine to 12 months. The potential for clinically important interactions exists because this drug is a potent inhibitor of drug metabolism. Studies and case reports have shown that isoniazid inhibits the metabolism of several drugs, including phenytoin, carbamazepine, anticoagulants, benzodiazepines, and vitamin D. Furthermore, isoniazid inhibits both monoamine oxidase and diamine oxidase (histaminase). Additional study is required to document the clinical significance of other isoniazid interactions. Future investigations will identify new isoniazid interactions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3890202     DOI: 10.1097/00007611-198506000-00025

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  9 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Interaction between isoniazid and valproate: a case of valproate overdosage.

Authors:  A P Jonville; A S Gauchez; E Autret; C Billard; P Barbier; F Nsabiyumva; M Breteau
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions.

Authors:  Kari A Mergenhagen; Bethany A Wattengel; Megan K Skelly; Collin M Clark; Thomas A Russo
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Lowering of theophylline clearance by isoniazid in slow and rapid acetylators.

Authors:  B Santoso
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

Review 5.  Interactions between the cytochrome P450 system and the second-generation antipsychotics.

Authors:  Trevor I Prior; Glen B Baker
Journal:  J Psychiatry Neurosci       Date:  2003-03       Impact factor: 6.186

Review 6.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 7.  Neurological manifestations and toxicities of the antituberculosis drugs. A review.

Authors:  M R Holdiness
Journal:  Med Toxicol       Date:  1987 Jan-Feb

8.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

Review 9.  Clinical pharmacokinetics of clofazimine. A review.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.